Caspofungin: Difference between revisions

Jump to navigation Jump to search
Ahmed Zaghw (talk | contribs)
No edit summary
Ahmed Zaghw (talk | contribs)
Line 4: Line 4:


==Overview==
==Overview==
'''Caspofungin''' ([[International Nonproprietary Name|INN]]<ref>[http://www.emea.europa.eu/htms/human/epar/c.htm European Medicines Agency's list of authorised medicines for human use (C)]</ref>) (brand name '''Cancidas''' worldwide) is a lipopeptide [[Antifungal medication|antifungal]] drug from [[Merck & Co.|Merck & Co., Inc.]].  It is a member of a new class of antifungals termed the [[echinocandin]]s. It works by inhibiting the [[enzyme]] [[1,3-Beta-glucan synthase|(1→3)-β-<small>D</small>-glucan synthase]] and thereby disturbing the integrity of the fungal [[cell wall]]. Caspofungin was the first inhibitor of fungal (1→3)-β-<small>D</small>-glucan synthesis to be approved by the United States Food and Drug Administration.<ref>{{cite journal|title=Caspofungin|author=Deresinski SC|year=2003|volume=36|issue=11|pages=1445&ndash;1457|doi=10.1086/375080|journal=Clin Infect Dis|pmid=12766841|author-separator=,|author2=Stevens DA}}</ref>
Caspofungin is administered [[intravenously]].


==Category==
==Category==

Revision as of 04:08, 5 January 2014

Caspofungin
CANCIDAS® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Overview

Caspofungin (INN[1]) (brand name Cancidas worldwide) is a lipopeptide antifungal drug from Merck & Co., Inc.. It is a member of a new class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin was the first inhibitor of fungal (1→3)-β-D-glucan synthesis to be approved by the United States Food and Drug Administration.[2] Caspofungin is administered intravenously.

Category

Antifungal

US Brand Names

CANCIDAS®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages

Mechanism of Action

References

  1. European Medicines Agency's list of authorised medicines for human use (C)
  2. Deresinski SC; Stevens DA (2003). "Caspofungin". Clin Infect Dis. 36 (11): 1445&ndash, 1457. doi:10.1086/375080. PMID 12766841. Unknown parameter |author-separator= ignored (help)